# US 2025/0205290 A1 · Use and delivery of ammonia oxidizing microorganisms for treatment of neurodegenerative disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205290 A1
- Document ID: US20250205290A1
- Status: Published application
- Kind: A1
- Application number: 19/073,773
- Filed: 2025-03-07
- Published: 2025-06-26
- Earliest claimed: 2018-03-30
- Assignees: Aobiome LLC
- Applicants: Aobiome LLC
- Inventors: David R. Whitlock; Todd Krueger; Lauren Nicole Ambrogio
- Web page: https://patentgrep.com/patent/US20250205290A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0043: {Nose}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods of treating neurodegenerative disorders, neurocognitive disorders, mental disorders, neuropsychological disorders, and symptoms thereof by administering ammonia oxidizing microorganisms are disclosed. Preparations for treating disorders, including neurodegenerative disorders, neurocognitive disorders, mental disorders, neuropsychological disorders, and symptoms thereof including ammonia oxidizing microorganisms are disclosed. Kits including ammonia oxidizing microorganism preparations and devices for administering ammonia oxidizing preparations are provided.

## Claims

### Claim 1

A method of treating a neurodegenerative disorder or a symptom thereof in a subject, comprising:
administering to the subject an effective amount of a preparation comprising AOM,
thereby treating the neurodegenerative disorder or the symptom thereof in the subject.

### Claim 2

A method of treating a neurocognitive disorder or a symptom thereof in a subject, comprising:
administering to the subject an effective amount of a preparation comprising AOM,
thereby treating the neurocognitive disorder or the symptom thereof in the subject.

### Claim 3

The method of any of the preceding claims, wherein the neurocognitive disorder is associated with the neurodegenerative disorder.

### Claim 4

A method of treating a mental disorder or a symptom thereof in a subject, comprising:
administering to the subject an effective amount of a preparation comprising AOM,
thereby treating the mental disorder of the symptom thereof in the subject.

### Claim 5

A method of treating a neuropsychological disorder or symptom thereof in a subject, comprising:
administering to the subject an effective amount of a preparation comprising AOM,
thereby treating the neuropsychological disorder or the symptom thereof in the subject.

### Claim 6

The method of any of the preceding claims, wherein the mental disorder is accompanied by a physiological signal.

### Claim 7

The method of any of the preceding claims, wherein the physiological signal comprises or is associated with degeneration or death of nerve cells, e.g., neuropathy, or denervation.

### Claim 8

The method of any of the preceding claims, wherein the physiological signal comprises or is associated with an overabundance of nerve cells.

### Claim 9

The method of any of the preceding claims, wherein the physiological signal comprises or is associated with an ataxia or a dementia.

### Claim 10

The method of any of the preceding claims, wherein the mental disorder is not accompanied by a physiological signal.

### Claim 11

The method of any of the preceding claims, wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, Prion Disease, Motor Neuron Disease, Amyotrophic lateral sclerosis, Multiple sclerosis, Huntington's Disease, Spinocerebellar Ataxia, Spinal Muscular Atrophy, and Raynaud's Disease.

### Claim 12

The method of any of the preceding claims, wherein the neurodegenerative disorder is a neuropathy.

### Claim 13

The method of any of the preceding claims, wherein the neuropathy is associated with diabetes, leprosy, hyperglycemia-induced glycation, vitamin deficiency, medication (e.g., chemotherapy, antibiotics), traumatic injury, ischemia, radiation therapy, alcohol consumption, drug use (e.g., stimulant use, opiate use), tobacco use, immune system disease, viral infection, capillary rarefaction, denervation, or is a genetic or hereditary condition.

### Claim 14

The method of any of the preceding claims, wherein the neurodegenerative disorder is accompanied by an associated neurocognitive disorder.

### Claim 15

The method of any of the preceding claims, wherein a degree of the neurocognitive or mental disorder is major or mild, as defined in the Diagnostic and Statistical Manual of Mental Disorders V (DSM V).

### Claim 16

The method of any of the preceding claims, wherein a severity of the neurocognitive or mental disorder is mild, moderate, or severe, as defined in the Diagnostic and Statistical Manual of Mental Disorders V (DSM V).

### Claim 17

The method of any of the preceding claims, wherein the neurocognitive or mental disorder is recurring or a single episode.

### Claim 18

The method of any of the preceding claims, wherein the associated neurocognitive disorder is selected from the group consisting of neurocognitive disorder due to Alzheimer's Disease, neurocognitive disorder with Lewy Bodies, frontotemporal neurocognitive disorder, vascular neurocognitive disorder, neurocognitive disorder due to traumatic brain injury, substance or medication induced neurocognitive disorder, neurocognitive disorder due to Prion Disease, neurocognitive disorder due to Parkinson's Disease, neurocognitive disorder due to Huntington's Disease, neurocognitive disorder due to Multiple Etiologies, neurocognitive disorder due to hepatitis C, interferon induced neurocognitive disorder, neurocognitive disorder due to another specified disease, and an unspecified neurocognitive disorder.

### Claim 19

The method of any of the preceding claims, wherein the mental disorder is associated with at least one of: a neurodevelopmental disorder, a schizophrenia spectrum disorder, a psychotic disorder, a bipolar disorder, a depressive disorder, an anxiety disorder, an obsessive-compulsive disorder, a trauma and stressor related disorder, a dissociative disorder, a somatic symptom disorder, a feeding and eating disorder, an elimination disorder, a sleep-wake disorder, a sexual dysfunction, a gender dysphoria, a disruptive, impulse-control, or conduct disorder, a substance related or addictive disorder, a neurocognitive disorder, a personality disorder, a paraphilic disorder, and a medication-induced movement disorder or other adverse effect of medication.

### Claim 20

The method of any of the preceding claims, wherein the mental disorder is selected from the group consisting of anxiety, insomnia, obsessive-compulsive disorder, post-traumatic stress disorder, depression, autism, chronic fatigue, myalgic encephalomyelitis, bipolar disorder, schizophrenia, dementia, and postpartum depression or psychosis.

### Claim 21

The method of any of the preceding claims, wherein the mental disorder is associated with one or more of lyme disease, mitochondrial disorders, obesity, multiple chemical sensitivity, hepatitis C infection, metal fume fever, obstructive sleep apnea (or other sleep disturbance), prolonged exposure to hypobaric hypoxia (altitude sickness), post-infection disorders, carbon monoxide poisoning, dehydration, or malnutrition.

### Claim 22

The method of any of the preceding claims, wherein the neuropsychological disorder is associated with neurogenic inflammation, e.g., oxidative stress.

### Claim 23

The method of any of the preceding claims, wherein the neuropsychological disorder comprises an autoimmune disorder, e.g., associated with oxidative stress.

### Claim 24

The method of any of the preceding claims, wherein the neuropsychological disorder is associated with alcohol consumption, alcohol abuse, drug use, drug abuse (e.g. stimulant or opioid), tobacco use, or tobacco abuse.

### Claim 25

The method of any of the preceding claims, wherein the neuropsychological disorder is associated with psychological stress, e.g., as a result of abuse or trauma, e.g., maternal stress.

### Claim 26

The method of any of the preceding claims, wherein the neuropsychological disorder is associated with a structural, biochemical, or electrical abnormality in a nervous system tissue of the subject.

### Claim 27

The method of any of the preceding claims, wherein the neuropsychological disorder is selected from the group consisting of epilepsy, fibromyalgia, Morgellons, taupathy, hyperarousal, acute stress response, or body dysmorphic disorder.

### Claim 28

The method of any of the preceding claims, wherein the symptom of the neuropsychological disorder is selected from the group consisting of paralysis, muscle weakness, poor coordination, loss of sensation, seizures, eclampsia, preeclampsia, confusion, pain, altered levels of consciousness, anxiety, changes in sleep, changes in mood, changes in cognition or cognitive ability, circulation, changes in appetite, changes in sexual desire, tremors, essential tremors, brain fog, frailty, breathlessness, delirium, delusion, euphoria, mania, loss of inhibition, paranoia, hallucinations, white matter hyperintensities, flushing, and combinations thereof.

### Claim 29

The method of any of the preceding claims, wherein the neuropsychological disorder or the symptom thereof is a result of a traumatic injury to a nervous system tissue of the subject.

### Claim 30

The method of any of the preceding claims, further comprising selecting a patient in need of treatment for any of the above-referenced disorders.

### Claim 31

The method of any of the preceding claims, further comprising identifying a patient as having any of the above-referenced disorders.

### Claim 32

The method of any of the preceding claims, further comprising identifying a patient as requiring treatment for any of the above-referenced disorders.

### Claim 33

The method of any of the preceding claims, wherein the subject is predisposed for any of the above-referenced disorders, e.g., based on age, race, gender, habit, or heredity.

### Claim 34

The method of any of the preceding claims, wherein the subject has not been diagnosed with any of the above-referenced disorders.

### Claim 35

The method of any of the preceding claims, wherein the above-referenced disorder is a degenerative disorder, genetic disorder, or a hereditary disorder.

### Claim 36

The method of any of the preceding claims, wherein the preparation comprising AOM is administered to the subject orally, enterally, intranasally, parenterally, subcutaneously, ocularly, otically, or respiratorilly.

### Claim 37

The method of any of the preceding claims, wherein a deposit tissue, target tissue, or both is a mucous membrane of the subject.

### Claim 38

The method of any of the preceding claims, wherein the preparation comprising AOM is administered intranasally to a nasal cavity of a subject.

### Claim 39

The method of any of the preceding claims, wherein the nasal cavity of the subject is substantially cleared when the preparation is administered.

### Claim 40

The method of any of the preceding claims, wherein the preparation is administered subsequent to administration of an antibiotic or a nasal cavity cleansing preparation.

### Claim 41

The method of any of the preceding claims, wherein a target percentage of administered AOM are transferred to a central nervous system (CNS) of the subject.

### Claim 42

The method of any of the preceding claims, wherein a deposit tissue, target tissue, or both is associated with a nasal cavity of the subject.

### Claim 43

The method of any of the preceding claims, wherein a deposit tissue, target tissue, or both is a nasal cavity, septal wall, nasal valve, nostril, nasopharanyx, vestibular area, turbinate (e.g., inferior, middle, superior), meatus (e.g., inferior, middle, superior), concha (e.g., inferior, middle, superior), maxillary sinus, sphenoidal sinus, sphenoethmoidal recess, ethmoidal bulla, semi-lunar hiatus, nasolacrimal duct, frontonasal duct, or olfactory region of the subject.

### Claim 44

The method of any of the preceding claims, wherein the preparation comprising AOM is administered to the subject topically.

### Claim 45

The method of any of the preceding claims, wherein a target percentage of administered AOM are transferred to the skin of the subject.

### Claim 46

The method of any of the preceding claims, wherein the effective amount of the preparation is administered to a face of the subject.

### Claim 47

The method of any of the preceding claims, wherein the effective amount of the preparation is administered to a body of the subject.

### Claim 48

The method of any of the preceding claims, wherein the preparation is applied to one or more of the forehead, eye region, neck, scalp, head, shoulder, arm, hands, leg, underarm, torso, chest, feet, knee, ankle, or buttocks of the subject.

### Claim 49

The method of any of the preceding claims, wherein a deposit tissue, target tissue, or both is associated with skin of the subject.

### Claim 50

The method of any of the preceding claims, wherein the target tissue is associated with a desired systemic effect.

### Claim 51

The method of any of the preceding claims, wherein the desired systemic effect involves treatment of one or more of: headaches, cardiovascular diseases, inflammation, immune responses, autoimmune disorders, liver diseases, infections, neurological diseases, psychiatric disorders, nitric oxide disorders, urea cycle disorders, congestion, vasodilation disorders, skin diseases, wound healing, reactions to insect bites, ophthalmic disorders, connective tissue disorders, lyme disease, and certain viral, bacterial, or fungal infections.

### Claim 52

The method of any of the preceding claims, wherein administering an effective amount of the preparation promotes endothelial function.

### Claim 53

The method of any of the preceding claims, wherein administering an effective amount of the preparation changes or alters a level of nitrite or NO at a target tissue or in circulation.

### Claim 54

The method of any of the preceding claims, wherein administering an effective amount of the preparation modulates a microbiome associated with the intranasal system of the subject.

### Claim 55

The method of any of the preceding claims, wherein administering an effective amount of the preparation modulates a microbiome associated with the CNS of the subject.

### Claim 56

The method of any of the preceding claims, wherein administering an effective amount of the preparation modulates a microbiome associated with the skin of the subject.

### Claim 57

The method of any of the preceding claims, wherein administering an effective amount of the preparation modulates a systemic microbiome associated with a remote system, e.g., gastrointestinal system, circulatory system, respiratory system, endocrine system, or immune system, of the subject.

### Claim 58

The method of any of the preceding claims, wherein administering is device-assisted.

### Claim 59

The method of any of the preceding claims, wherein the preparation is administered prior to onset of a neuropsychological symptom.

### Claim 60

The method of any of the preceding claims, wherein the preparation is administered during incidence of a neuropsychological symptom.

### Claim 61

The method of any of the preceding claims, wherein the preparation is administered subsequent to the subsiding of a neuropsychological symptom.

### Claim 62

The method of any of the preceding claims, wherein the preparation is administered in response to a neuropsychological symptom, trigger or warning sign, e.g. paralysis, muscle weakness, poor coordination, loss of sensation, seizures, eclampsia, preeclampsia, confusion, pain, altered levels of consciousness, anxiety, changes in sleep, changes in mood, changes in cognition or cognitive ability, circulation, changes in appetite, changes in sexual desire, tremors, essential tremors, brain fog, frailty, breathlessness, delirium, delusion, euphoria, mania, loss of inhibition, paranoia, hallucinations, white matter hyperintensities, flushing, or combinations thereof.

### Claim 63

The method of any of the preceding claims, further comprising administering water or a buffer solution, e.g., an aqueous buffer solution, to the subject subsequent to administering the preparation.

### Claim 64

The method of any of the preceding claims, wherein the preparation is formulated as a drop, spray, aerosol, or mist.

### Claim 65

The method of any of the preceding claims, wherein the preparation includes microspheres or microcapsules.

### Claim 66

The method of any of the preceding claims, wherein the preparation is formulated to be compatible with the mucous membrane of the subject.

### Claim 67

The method of any of the preceding claims, wherein the preparation is formulated for immediate release or extended release.

### Claim 68

The method of any of the preceding claims, wherein the preparation is formulated to deliver nitrite or NO to a target tissue, locally or systemically.

### Claim 69

The method of any of the preceding claims, wherein the preparation is formulated for transmucosal delivery and/or circulation, e.g. locally or systemically.

### Claim 70

The method of any of the preceding claims, further comprising administering a second amount of the preparation to the subject.

### Claim 71

The method of any of the preceding claims, wherein the preparation is administered as part of a combination therapy.

### Claim 72

The method of any of the preceding claims, further comprising administering a second treatment in combination with the preparation.

### Claim 73

The method of any of the preceding claims, wherein the preparation is administered for a period of time prior to initiating the second treatment.

### Claim 74

The method of any of the preceding claims, wherein the preparation is administered concurrently with the second treatment.

### Claim 75

The method of any of the preceding claims, wherein the preparation is administered for a period of time subsequent to ceasing the second treatment.

### Claim 76

The method of any of the preceding claims, wherein the second treatment is administered via an alternate mode of administration, e.g. via inhalation or enteral technique.

### Claim 77

The method of any of the preceding claims, wherein the subject has a therapeutic level of a second treatment.

### Claim 78

The method of any of the preceding claims, wherein the preparation is administered in conjunction with an anti-inflammatory agent.

### Claim 79

The method of any of the preceding claims, wherein the preparation is administered in conjunction with a medical approach that treats, e.g., is approved to treat or is commonly used to treat, the relevant disease or disorder, or a symptom of the relevant disease or disorder.

### Claim 80

The method of any of the preceding claims, wherein the preparation is administered before or after a surgical or diagnostic procedure.

### Claim 81

The method of any of the preceding claims, wherein the preparation is administered in conjunction with a decongestant, probiotic, therapeutic, exercise, or stress management.

### Claim 82

The method of any of the preceding claims, wherein the preparation is administered in combination with a therapeutic treatment for Alzheimer's Disease, Parkinson's Disease, Prion Disease, Motor Neuron Disease, Amyotrophic lateral sclerosis, Multiple sclerosis, Huntington's Disease, Spinocerebellar Ataxia, Spinal Muscular Atrophy, or Raynaud's Disease.

### Claim 83

The method of any of the preceding claims, wherein the preparation is administered in combination with a therapeutic treatment for anxiety, insomnia, obsessive-compulsive disorder, post-traumatic stress disorder, depression, autism, chronic fatigue, myalgic encephalomyelitis, bipolar disorder, schizophrenia, dementia, or postpartum depression or psychosis.

### Claim 84

The method of any of the preceding claims, wherein an amount and/or a frequency of administration is sufficient to reduce incidence of paralysis, muscle weakness, poor coordination, loss of sensation, seizures, eclampsia, preeclampsia, confusion, pain, chronic pain, altered levels of consciousness, anxiety, changes in sleep, changes in mood, changes in cognition or cognitive ability, circulation, changes in appetite, changes in sexual desire, tremors, essential tremors, brain fog, frailty, breathlessness, delirium, delusion, euphoria, mania, loss of inhibition, paranoia, hallucinations, white matter hyperintensities, flushing, or combinations thereof.

### Claim 85

The method of any of the preceding claims, wherein an amount and/or a frequency of administration is sufficient to treat anxiety, insomnia, obsessive-compulsive disorder, post-traumatic stress disorder, depression, autism, chronic fatigue, myalgic encephalomyelitis, bipolar disorder, schizophrenia, dementia, or postpartum depression or psychosis.

### Claim 86

The method of any of the preceding claims, wherein the preparation is administered in conjunction with nitrite, nitrate, and/or NO.

### Claim 87

The method of any of the preceding claims, wherein the effective amount is a therapeutically effective dose of AOM.

### Claim 88

The method of any of the preceding claims, wherein the therapeutically effective dose of AOM is about or greater than about 1×103, 104, 105, 106, 107, 108, 109, 1010, 1011, 1012, 1013, or 1014 CFU.

### Claim 89

The method of any of the preceding claims, wherein the preparation is administered as an analgesic.

### Claim 90

The method of any of the preceding claims, wherein the preparation is administered as a prophylactic.

### Claim 91

The method of any of the preceding claims, wherein the preparation is self-administered.

### Claim 92

The method of any of the preceding claims, wherein the preparation is administered about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 times per day.

### Claim 93

The method of any of the preceding claims, wherein the preparation is administered for about 1-3, 3-5, 5-7, 7-9, 5-10, 10-14, 12-18, 12-21, 21-28, 28-35, 35-42, 42-49, 49-56, 46-63, 63-70, 70-77, 77-84, or 84-91 days.

### Claim 94

The method of any of the preceding claims, wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes of the subject waking from sleep.

### Claim 95

The method of any of the preceding claims, wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes prior to the subject sleeping.

### Claim 96

The method of any of the preceding claims, wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes of the subject eating.

### Claim 97

The method of any of the preceding claims, wherein the preparation is administered 30, 60, 90, 120, 150, or 180 minutes before the subject cleanses or showers.

### Claim 98

The method of any of the preceding claims, wherein the subject is female.

### Claim 99

The method of any of the preceding claims, wherein the subject is male.

### Claim 100

The method of any of the preceding claims, wherein the subject is characterized as one of the following ethnicity/race: Asian, black or African American, Hispanic or Latino, white, or multi-racial.

### Claim 101

The method of any of the preceding claims, wherein the subject has a disrupted microbiome.

### Claim 102

The method of any of the preceding claims, wherein the subject is of an age less than 1, or between 1-5, 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, or over 60 years.

### Claim 103

The method of any of the preceding claims, wherein the preparation comprises AOM in a buffer solution, e.g., an aqueous buffer solution.

### Claim 104

The method of any of the preceding claims, wherein the buffer solution, e.g., aqueous buffer solution, comprises disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 105

The method of any of the preceding claims, wherein the buffer solution e.g., aqueous buffer solution, consisting essentially of disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 106

The method of any of the preceding claims, wherein the buffer solution, e.g., aqueous buffer solution, consists of disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 107

The method of any of the preceding claims, wherein the preparation is characterized by a physiological pH level.

### Claim 108

The method of any of the preceding claims, wherein the preparation further comprises or is administered concurrently with a compound that promotes growth or metabolism of the AOM, NO production, and/or urease activity.

### Claim 109

The method of any of the preceding claims, wherein the preparation comprises at least one of ammonia, ammonium salts, and urea.

### Claim 110

The method of any of the preceding claims, wherein the preparation comprises a controlled release material, e.g., slow release material.

### Claim 111

The method of any of the preceding claims, wherein the preparation further comprises an excipient, e.g., a pharmaceutically acceptable excipient.

### Claim 112

The method of any of the preceding claims, wherein the excipient comprises an absorption or penetration enhancer, preservative, antioxidant, buffer, chelating agent, ion exchange agent, solubilizing agent, suspending agent, thickener, surfactant, wetting agent, tonicity-adjusting agent, enzyme inhibitor, or vehicle for proper drug delivery.

### Claim 113

The method of any of the preceding claims, wherein the preparation comprises a mucoadhesive agent.

### Claim 114

The method of any of the preceding claims, wherein the preparation includes a disintegrant, chelator, coating agent, modified-release product, or filler.

### Claim 115

The method of any of the preceding claims, wherein the preparation is substantially free of other organisms.

### Claim 116

The method of any of the preceding claims, wherein the preparation comprises between about 1×103 CFU/mL to about 1×1014 CFU/mL AOM.

### Claim 117

The method of any of the preceding claims, wherein the preparation comprises between about 1×109 CFU/mL to about 10×109 CFU/mL AOM.

### Claim 118

The method of any of the preceding claims, wherein the AOM comprise ammonia oxidizing bacteria (AOB).

### Claim 119

The method of any of the preceding claims, wherein the AOM consist essentially of AOB.

### Claim 120

The method of any of the preceding claims, wherein the AOM consist of AOB.

### Claim 121

The method of any of the preceding claims, wherein the AOM comprise Nitrosomonas, Nitrosococcus, Nitrosospira, Nitrosocystis, Nitrosolobus, Nitrosovibrio, and combinations thereof.

### Claim 122

The method of any of the preceding claims, wherein the AOM is Nitrosomonas eutropha (N. eutropha).

### Claim 123

The method of any of the preceding claims, wherein the AOM is N. eutropha D23, having ATCC accession number PTA-121157.

### Claim 124

The method of any of the preceding claims, wherein the AOM comprise ammonia oxidizing archaea (AOA).

### Claim 125

The method of any of the preceding claims, wherein the AOM are capable of converting ammonia or ammonium to nitrite at a rate of at least about 1 pmol/min/mg protein, e.g., at least about 0.1 nmol/min/mg protein.

### Claim 126

The method of any of the preceding claims, wherein the preparation is administered, e.g., intranasally to a first tissue, e.g. a deposit tissue.

### Claim 127

The method of any of the preceding claims, wherein the first tissue is the target tissue.

### Claim 128

The method of any of the preceding claims, wherein the first tissue is other than the target tissue, e.g., the preparation is applied to a first tissue and the preparation, or a product of the preparation, e.g., NO, is transported, e.g., by diffusion, to a second tissue, e.g. the target tissue.

### Claim 129

The method of any of the preceding claims, wherein the second treatment comprises a surgical procedure.

### Claim 130

The method of any of the preceding claims, wherein the excipient comprises an anti-adherent, binder, coat, disintegrant, filler, flavor, color, lubricant, glidant, sorbent preservative, or sweetener.

### Claim 131

The method of any of the preceding claims, wherein a biome-friendly product is used in connection with the administered preparation comprising AOM.

### Claim 132

A preparation comprising AOM, as recited in any of the preceding claims, for treatment of a neurodegenerative disorder or a symptom thereof in a subject.

### Claim 133

A preparation comprising AOM, as recited in any of the preceding claims, for treatment of a neurocognitive disorder or a symptom thereof in a subject.

### Claim 134

A preparation comprising AOM, as recited in any of the preceding claims, for treatment of a neuropsychological disorder or a symptom thereof in a subject.

### Claim 135

A preparation comprising AOM, as recited in any of the preceding claims, for treatment of a mental disorder or a symptom thereof in a subject.

### Claim 136

The preparation of any of the preceding claims, wherein the preparation is packaged for single use.

### Claim 137

The preparation of any of the preceding claims, wherein the preparation is packaged for multiple use.

### Claim 138

The preparation of any of the preceding claims, comprising AOM and other organisms, e.g., a community of organisms.

### Claim 139

The preparation of any of the preceding claims, wherein the preparation is a spray, aerosol, or mist.

### Claim 140

A kit comprising a preparation comprising AOM as recited in any of the preceding claims.
